4basebio 产品代理
4basebio 产品代理
4basebio一开始专注于制造用于基因治疗的合成DNA；与目前的质粒DNA相比，我们合成的DNA具有明显的安全性、有效性和成本效益。我们的近期目标是开发良好生产规范（“GMP”）级合成DNA，作为该核心技术商业化的关键里程碑。
在验证和扩展我们的DNA时，我们发现了解决基因治疗价值链上互补领域的机会。
我们最近成立的发现业务专注于测试和开发用于非病毒核酸输送的纳米颗粒。除此之外，4basebio还与在实验室环境中实现了相关细胞类型的基因表达的合作伙伴进行了一系列适应症合作。我们的目标是将这项技术与我们的交付技术和合成DNA结合起来，通过概念验证、临床前和其他方式推进新的潜在疗法。
4basebio拥有专有技术，将使其在基因治疗和疫苗应用的合成DNA制造领域处于领先地位。我们的目标是将这项技术与创新的非病毒DNA递送平台结合起来，提供更好、更安全的基因疗法和DNA疫苗。
Non-viral nanoparticle design and optimisation
Payload production
HTvivoTM: Multiplexed in vivo vector validation
CMC and Regulatory
4basebio PLC is developing next generation gene therapy technologies and solutions.
4basebio started with a focus on the manufacture of synthetic DNA for use in gene therapies; our synthetic DNA has clear safety, efficacy, and cost benefits over current plasmid DNA. Our near-term objective is the development of Good Manufacturing Practice (“GMP”) grade synthetic DNA as a key milestone in the commercialisation of this core technology.
In validating and scaling our DNA, we have identified opportunities to address complementary areas along the gene therapy value chain.
Our recently established discovery business focusses on the testing and development of nanoparticles for use in non-viral delivery of nucleic acids. Alongside this, 4basebio is collaborating across a range of indications with partners who have achieved gene expression in relevant cell types in laboratory settings. Our ambition is to combine this know-how with our delivery technology and synthetic DNA to advance new potential therapies through proof of concept, pre-clinical and beyond.
At the heart of the business will be our ability to manufacture GMP grade synthetic DNA and non-viral nanoparticles for third party customers; and develop the combination of technologies and expertise into gene therapy solutions for further clinical development and commercialisation.
4basebio owns proprietary technology which will place it at the forefront of synthetic DNA manufacture for gene therapy and vaccine applications. We aim to combine this technology with an innovative non-viral DNA delivery platform to offer better and safer gene therapies and DNA vaccines.
